Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Non-alcoholic Fatty Liver Disease | 28 | 2020 | 907 | 7.13 | Why? |
| Keto Acids | 2 | 2019 | 6 | 1.57 | Why? |
| Mitochondria, Liver | 2 | 2019 | 18 | 1.56 | Why? |
| Fructose | 2 | 2018 | 52 | 1.37 | Why? |
| Fatty Liver | 4 | 2021 | 299 | 1.33 | Why? |
| Breath Tests | 2 | 2019 | 338 | 1.16 | Why? |
| Uric Acid | 2 | 2018 | 285 | 1.08 | Why? |
| Liver | 12 | 2020 | 4007 | 1.05 | Why? |
| Metabolic Syndrome | 4 | 2019 | 810 | 1.00 | Why? |
| Lipase | 3 | 2019 | 153 | 0.99 | Why? |
| Carbon Isotopes | 2 | 2019 | 141 | 0.92 | Why? |
| Insulin Resistance | 3 | 2018 | 669 | 0.81 | Why? |
| Fatty Liver, Alcoholic | 1 | 2018 | 13 | 0.78 | Why? |
| Bifidobacterium animalis | 1 | 2018 | 5 | 0.76 | Why? |
| Calcinosis | 2 | 2018 | 240 | 0.74 | Why? |
| Apolipoproteins | 1 | 2018 | 33 | 0.72 | Why? |
| Oligosaccharides | 1 | 2018 | 69 | 0.71 | Why? |
| Energy Drinks | 1 | 2017 | 18 | 0.71 | Why? |
| Receptors, Cytoplasmic and Nuclear | 1 | 2017 | 67 | 0.68 | Why? |
| Eicosapentaenoic Acid | 1 | 2018 | 106 | 0.67 | Why? |
| Diabetes Mellitus, Type 2 | 10 | 2019 | 6166 | 0.66 | Why? |
| Hypercholesterolemia | 1 | 2018 | 175 | 0.65 | Why? |
| Hyperuricemia | 1 | 2018 | 160 | 0.65 | Why? |
| Obesity, Metabolically Benign | 1 | 2016 | 20 | 0.65 | Why? |
| Liver Cirrhosis | 5 | 2020 | 1810 | 0.64 | Why? |
| Fibroblast Growth Factors | 1 | 2017 | 119 | 0.64 | Why? |
| Docosahexaenoic Acids | 1 | 2018 | 145 | 0.63 | Why? |
| Bone Density | 1 | 2018 | 335 | 0.59 | Why? |
| Ceramides | 3 | 2019 | 80 | 0.56 | Why? |
| RNA, Ribosomal, 16S | 1 | 2018 | 793 | 0.56 | Why? |
| Myocardial Ischemia | 2 | 2018 | 781 | 0.56 | Why? |
| Membrane Proteins | 3 | 2019 | 1733 | 0.53 | Why? |
| Weight Loss | 1 | 2018 | 826 | 0.46 | Why? |
| Extracellular Vesicles | 1 | 2018 | 607 | 0.43 | Why? |
| Lipids | 1 | 2018 | 1079 | 0.43 | Why? |
| Leukocytes | 1 | 2018 | 1046 | 0.43 | Why? |
| Coronary Angiography | 3 | 2019 | 2275 | 0.42 | Why? |
| Gastrointestinal Tract | 1 | 2018 | 1113 | 0.40 | Why? |
| Coronary Artery Disease | 3 | 2018 | 2570 | 0.39 | Why? |
| Vascular Diseases | 1 | 2017 | 846 | 0.37 | Why? |
| Renal Insufficiency, Chronic | 3 | 2018 | 2654 | 0.36 | Why? |
| Cardiomyopathies | 1 | 2017 | 997 | 0.35 | Why? |
| Gastrointestinal Microbiome | 2 | 2018 | 1961 | 0.34 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 1510 | 0.33 | Why? |
| Diagnostic Tests, Routine | 1 | 2018 | 2643 | 0.32 | Why? |
| Coronary Circulation | 2 | 2018 | 188 | 0.31 | Why? |
| Obesity | 5 | 2019 | 7388 | 0.31 | Why? |
| Inflammation | 2 | 2018 | 13255 | 0.29 | Why? |
| Diet | 1 | 2018 | 2052 | 0.29 | Why? |
| Triglycerides | 2 | 2018 | 478 | 0.29 | Why? |
| Cholesterol, LDL | 2 | 2018 | 499 | 0.27 | Why? |
| Cholesterol, HDL | 2 | 2018 | 439 | 0.27 | Why? |
| Biomarkers | 7 | 2020 | 23361 | 0.26 | Why? |
| Physical Fitness | 1 | 2007 | 334 | 0.26 | Why? |
| Diabetes Mellitus, Type 1 | 1 | 2017 | 1969 | 0.25 | Why? |
| Cardiovascular Diseases | 6 | 2018 | 11497 | 0.25 | Why? |
| Energy Metabolism | 1 | 2007 | 451 | 0.25 | Why? |
| Risk Factors | 17 | 2021 | 71621 | 0.22 | Why? |
| Coronary Vessels | 2 | 2019 | 914 | 0.21 | Why? |
| Diet, Fat-Restricted | 1 | 2018 | 15 | 0.19 | Why? |
| Myocardial Perfusion Imaging | 2 | 2018 | 218 | 0.19 | Why? |
| Genes, Microbial | 1 | 2018 | 10 | 0.19 | Why? |
| Cultured Milk Products | 1 | 2018 | 3 | 0.19 | Why? |
| Dipyridamole | 1 | 2018 | 52 | 0.19 | Why? |
| Synbiotics | 1 | 2018 | 15 | 0.19 | Why? |
| Body Mass Index | 4 | 2019 | 4306 | 0.18 | Why? |
| Cardiac Conduction System Disease | 1 | 2018 | 44 | 0.18 | Why? |
| Vitamin E | 1 | 2019 | 128 | 0.18 | Why? |
| Humans | 49 | 2021 | 930598 | 0.18 | Why? |
| Logistic Models | 3 | 2018 | 9089 | 0.18 | Why? |
| Hypolipidemic Agents | 1 | 2020 | 208 | 0.18 | Why? |
| Weight Reduction Programs | 1 | 2019 | 87 | 0.18 | Why? |
| Adipose Tissue | 2 | 2018 | 612 | 0.18 | Why? |
| Absorptiometry, Photon | 1 | 2018 | 168 | 0.18 | Why? |
| Dietary Fats | 1 | 2018 | 96 | 0.18 | Why? |
| Glucose Intolerance | 1 | 2019 | 115 | 0.18 | Why? |
| Hyperlipidemias | 1 | 2020 | 290 | 0.18 | Why? |
| Leucine | 1 | 2018 | 121 | 0.17 | Why? |
| Diabetes Complications | 2 | 2020 | 2358 | 0.17 | Why? |
| Obesity, Abdominal | 1 | 2019 | 167 | 0.17 | Why? |
| Gene Silencing | 1 | 2018 | 213 | 0.17 | Why? |
| S100 Calcium Binding Protein beta Subunit | 1 | 2017 | 63 | 0.17 | Why? |
| Morus | 1 | 2017 | 41 | 0.16 | Why? |
| Elasticity Imaging Techniques | 1 | 2019 | 194 | 0.16 | Why? |
| Bile Acids and Salts | 1 | 2017 | 91 | 0.16 | Why? |
| Prediabetic State | 1 | 2019 | 200 | 0.16 | Why? |
| Hypertriglyceridemia | 1 | 2018 | 90 | 0.16 | Why? |
| Tomography, Emission-Computed, Single-Photon | 1 | 2018 | 279 | 0.16 | Why? |
| Blood Flow Velocity | 1 | 2017 | 193 | 0.16 | Why? |
| Bone and Bones | 1 | 2018 | 235 | 0.15 | Why? |
| Male | 25 | 2021 | 367725 | 0.15 | Why? |
| Apolipoprotein A-I | 1 | 2017 | 148 | 0.15 | Why? |
| Coronary Stenosis | 1 | 2019 | 273 | 0.15 | Why? |
| Female | 25 | 2021 | 380317 | 0.15 | Why? |
| Glomerular Filtration Rate | 2 | 2019 | 1262 | 0.15 | Why? |
| Vasodilator Agents | 1 | 2018 | 344 | 0.15 | Why? |
| Proteinuria | 1 | 2019 | 474 | 0.15 | Why? |
| Adolescent | 10 | 2021 | 86841 | 0.15 | Why? |
| Republic of Korea | 2 | 2018 | 5858 | 0.15 | Why? |
| Metabolic Diseases | 1 | 2021 | 505 | 0.14 | Why? |
| Antineoplastic Agents, Hormonal | 1 | 2017 | 203 | 0.14 | Why? |
| Proof of Concept Study | 1 | 2017 | 696 | 0.14 | Why? |
| Case-Control Studies | 3 | 2018 | 17671 | 0.14 | Why? |
| Fluorescent Antibody Technique | 1 | 2017 | 835 | 0.14 | Why? |
| Fatty Acids, Omega-3 | 1 | 2018 | 306 | 0.14 | Why? |
| Exercise | 2 | 2019 | 6771 | 0.13 | Why? |
| Drug Resistance, Neoplasm | 1 | 2017 | 447 | 0.13 | Why? |
| Lipid Metabolism | 1 | 2018 | 572 | 0.13 | Why? |
| Magnetic Resonance Spectroscopy | 1 | 2018 | 881 | 0.12 | Why? |
| Ultrasonography | 2 | 2019 | 4409 | 0.12 | Why? |
| Alleles | 1 | 2018 | 1557 | 0.12 | Why? |
| Pediatric Obesity | 1 | 2018 | 492 | 0.12 | Why? |
| Up-Regulation | 1 | 2020 | 2249 | 0.12 | Why? |
| Exercise Test | 1 | 2018 | 911 | 0.12 | Why? |
| Middle Aged | 18 | 2021 | 270681 | 0.11 | Why? |
| Biopsy | 2 | 2019 | 2811 | 0.11 | Why? |
| Body Weight | 1 | 2018 | 1074 | 0.11 | Why? |
| Linear Models | 1 | 2018 | 1914 | 0.11 | Why? |
| Colonoscopy | 1 | 2018 | 738 | 0.11 | Why? |
| Adult | 15 | 2021 | 244371 | 0.11 | Why? |
| Down-Regulation | 1 | 2017 | 1416 | 0.11 | Why? |
| Child | 7 | 2019 | 70012 | 0.11 | Why? |
| Aortic Valve | 1 | 2017 | 664 | 0.11 | Why? |
| Area Under Curve | 1 | 2018 | 2564 | 0.10 | Why? |
| Insulin | 2 | 2017 | 1316 | 0.10 | Why? |
| Incidence | 5 | 2019 | 25622 | 0.10 | Why? |
| Double-Blind Method | 2 | 2018 | 5988 | 0.10 | Why? |
| Antioxidants | 1 | 2019 | 1593 | 0.10 | Why? |
| Aortic Valve Stenosis | 1 | 2017 | 741 | 0.09 | Why? |
| Computed Tomography Angiography | 1 | 2018 | 2153 | 0.09 | Why? |
| Coronary Disease | 1 | 2014 | 645 | 0.09 | Why? |
| Patient Readmission | 1 | 2017 | 1543 | 0.08 | Why? |
| Health Surveys | 1 | 2018 | 2841 | 0.08 | Why? |
| Multivariate Analysis | 1 | 2018 | 5440 | 0.08 | Why? |
| Monitoring, Physiologic | 1 | 2018 | 1956 | 0.08 | Why? |
| Prevalence | 6 | 2019 | 25773 | 0.08 | Why? |
| Atrial Fibrillation | 2 | 2019 | 2320 | 0.08 | Why? |
| Blood Glucose | 2 | 2020 | 3642 | 0.08 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.08 | Why? |
| Endothelial Cells | 1 | 2017 | 2048 | 0.08 | Why? |
| Hypoglycemic Agents | 1 | 2019 | 2165 | 0.08 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.08 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.07 | Why? |
| Plant Extracts | 1 | 2017 | 1514 | 0.07 | Why? |
| Evidence-Based Medicine | 1 | 2018 | 3228 | 0.07 | Why? |
| Aged | 12 | 2021 | 215776 | 0.07 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.07 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 7868 | 0.07 | Why? |
| Severity of Illness Index | 4 | 2021 | 48226 | 0.07 | Why? |
| Kidney | 1 | 2019 | 3648 | 0.07 | Why? |
| Colorectal Neoplasms | 1 | 2018 | 1884 | 0.07 | Why? |
| Analysis of Variance | 1 | 2007 | 950 | 0.07 | Why? |
| Kidney Failure, Chronic | 1 | 2020 | 3222 | 0.07 | Why? |
| Genetic Predisposition to Disease | 1 | 2018 | 4027 | 0.06 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.06 | Why? |
| Body Composition | 1 | 2007 | 414 | 0.06 | Why? |
| Liver Diseases | 1 | 2019 | 2698 | 0.06 | Why? |
| Chronic Disease | 1 | 2017 | 5139 | 0.06 | Why? |
| Cross-Sectional Studies | 6 | 2019 | 53120 | 0.06 | Why? |
| Interleukin-6 | 1 | 2021 | 7522 | 0.06 | Why? |
| Magnetic Resonance Imaging | 1 | 2019 | 6551 | 0.06 | Why? |
| Disease Progression | 2 | 2018 | 13580 | 0.06 | Why? |
| Reproducibility of Results | 1 | 2019 | 11304 | 0.06 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.06 | Why? |
| Europe | 1 | 2018 | 12702 | 0.06 | Why? |
| Observational Studies as Topic | 2 | 2020 | 1887 | 0.05 | Why? |
| Cardiovascular Infections | 1 | 2020 | 27 | 0.05 | Why? |
| Disease Management | 1 | 2019 | 6841 | 0.05 | Why? |
| Reproductive Tract Infections | 1 | 2020 | 45 | 0.05 | Why? |
| Algorithms | 1 | 2018 | 7346 | 0.05 | Why? |
| Arrhythmias, Cardiac | 1 | 2014 | 2510 | 0.05 | Why? |
| Prognosis | 3 | 2018 | 32490 | 0.05 | Why? |
| Acute Kidney Injury | 1 | 2020 | 5762 | 0.05 | Why? |
| Regression Analysis | 1 | 2007 | 2484 | 0.05 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.05 | Why? |
| Breast Neoplasms | 1 | 2017 | 3633 | 0.05 | Why? |
| Tissue Array Analysis | 1 | 2017 | 75 | 0.04 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.04 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.04 | Why? |
| Cohort Studies | 2 | 2018 | 36005 | 0.04 | Why? |
| MCF-7 Cells | 1 | 2017 | 199 | 0.04 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.04 | Why? |
| Xenograft Model Antitumor Assays | 1 | 2017 | 274 | 0.04 | Why? |
| Tamoxifen | 1 | 2017 | 83 | 0.04 | Why? |
| Fibrosis | 1 | 2020 | 800 | 0.04 | Why? |
| Glucose Tolerance Test | 1 | 2017 | 238 | 0.04 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.04 | Why? |
| Age of Onset | 1 | 2018 | 557 | 0.04 | Why? |
| Hospital Mortality | 1 | 2020 | 22087 | 0.04 | Why? |
| Lipoproteins, HDL | 1 | 2017 | 154 | 0.04 | Why? |
| Heart Failure | 1 | 2017 | 6638 | 0.04 | Why? |
| Chromatography, Liquid | 1 | 2018 | 640 | 0.04 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.04 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.03 | Why? |
| Electrocardiography | 2 | 2019 | 3957 | 0.03 | Why? |
| Global Health | 1 | 2017 | 13911 | 0.03 | Why? |
| Risk Assessment | 1 | 2018 | 25439 | 0.03 | Why? |
| Cross-Over Studies | 1 | 2017 | 867 | 0.03 | Why? |
| Aged, 80 and over | 6 | 2019 | 88759 | 0.03 | Why? |
| Hematologic Diseases | 1 | 2020 | 614 | 0.03 | Why? |
| Microcirculation | 1 | 2017 | 447 | 0.03 | Why? |
| Tandem Mass Spectrometry | 1 | 2018 | 1031 | 0.03 | Why? |
| Urologic Diseases | 1 | 2020 | 860 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2019 | 25144 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2017 | 1654 | 0.03 | Why? |
| Retrospective Studies | 5 | 2021 | 105322 | 0.03 | Why? |
| Treatment Outcome | 1 | 2018 | 51732 | 0.03 | Why? |
| Glycated Hemoglobin A | 1 | 2019 | 1316 | 0.03 | Why? |
| Neoplasm Recurrence, Local | 1 | 2017 | 1063 | 0.02 | Why? |
| Pandemics | 6 | 2020 | 389249 | 0.02 | Why? |
| Cell Line, Tumor | 1 | 2017 | 3608 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| Gastrointestinal Diseases | 1 | 2020 | 2580 | 0.02 | Why? |
| Child, Preschool | 2 | 2019 | 36283 | 0.02 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.02 | Why? |
| Myocardium | 1 | 2014 | 2323 | 0.01 | Why? |
| Nervous System Diseases | 1 | 2020 | 4092 | 0.01 | Why? |
| Comorbidity | 2 | 2018 | 34796 | 0.01 | Why? |
| Life Style | 1 | 2014 | 2708 | 0.01 | Why? |
| Signal Transduction | 1 | 2017 | 7207 | 0.01 | Why? |
| United Kingdom | 1 | 2020 | 18046 | 0.01 | Why? |
| Mass Screening | 1 | 2018 | 8005 | 0.01 | Why? |
| Mice | 1 | 2017 | 21357 | 0.01 | Why? |
| Research Design | 1 | 2014 | 5830 | 0.01 | Why? |
| Infant, Newborn | 1 | 2018 | 23105 | 0.01 | Why? |
| Infant | 1 | 2018 | 30274 | 0.01 | Why? |
| China | 1 | 2021 | 50654 | 0.01 | Why? |
| Prospective Studies | 1 | 2017 | 43301 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |
| Animals | 1 | 2017 | 78931 | 0.01 | Why? |
Byrne's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(232)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(64)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_